Left Atrial Reservoir Strain Improves Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy

Background: Current risk scores for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) have limited ability to identify high-risk subgroups. We aimed to investigate the prognostic value of left atrial reservoir strain (LARS) for SCD-related events and its utility for risk stratification.Methods: This retrospective cohort study included 1,761 patients with HCM from two referral centers.… Continue reading Left Atrial Reservoir Strain Improves Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy

Multimodality imaging in #hypertrophic #cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by unexplained myocardial hypertrophy. Although the diagnosis of HCM is traditionally based on increased left ventricular (LV) wall thickness, contemporary management requires a comprehensive multimodality imaging approach to accurately define disease phenotype, assess functional consequences, and guide risk stratification. Transthoracic echocardiography remains the first-line imaging modality, providing… Continue reading Multimodality imaging in #hypertrophic #cardiomyopathy

Mavacamten for treatment of symptomatic obstructive #hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated and are not disease-specific. We aimed to assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic… Continue reading Mavacamten for treatment of symptomatic obstructive #hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial